

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>Bombay Stock Exchange Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
Date: June 24, 2015	
Re.: Press Release.	


Dear Sir / Madam,

We enclose herewith a copy of press release dated June 24, 2015 under the title **“Zydus receives final approval for Pyridostigmine Bromide Tablets”**. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above.

Zydus receives final approval for Pyridostigmine Bromide Tablets

Ahmedabad, 24 June 2015

Zydus Cadila has received the final approval from the USFDA to market Pyridostigmine Bromide Tablets USP, 60 mg.

The estimated sales in 2015 for Pyridostigmine Bromide Tablets USP which is used in the treatment of various neurological disorders is USD 27.9 million as per IMS.

The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.
